9342-8530 Quebec Inc DGCRF

additional old research comments (2005)

[ready2go1]

Investment Rewards

DiagnoCure’s PCA3 marker may offer unique advantages over the

currently used PSA test, which could lead to widespread adoption and a

dominant position in the prostate cancer screening market, estimated at

45 million PSA tests annually. Prostate cancer screening is recommended for all

men over 50, but the current screening technology has significant shortcomings,

as it is not able to differentiate between prostate cancer and other benign

conditions. As the most prostate cancer-specific marker described to date, PCA3

has shown superior sensitivity and specificity compared with the PSA test. We

expect the PCA3 test to be used, initially, for patients with an elevated PSA

and previous negative biopsies, in order to reduce the number of unnecessary and

costly biopsies being conducted. Based on our discussions with urologists, who

indicated that a novel marker with better sensitivity and specificity than PSA

would be a welcome improvement, we believe that over the long term, the PCA3

test could displace the PSA test as a screening tool for prostate cancer.

We believe that the wider adoption of PCA3 testing could drive between

$10.00/sh and $20.00/sh in upside to our current valuation of DiagnoCure.